Follow up of Patients With Aortic Aneurysm by Dosage of Circulant Endothelial Progenitor Cells

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02919709

Acronym

ANOPEC 3

Enrollment

Registered

2016-09-29

Start date

2013-11-30

Completion date

2018-11-30

Last updated

2018-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thoracic or Abdominal Aortic Aneurysm With no Indication for Surgical Treatment

Brief summary

The study aims to investigate the existence of a reliable correlation between the progression of aortic diameters and blood levels of circulant endothelial progenitor cells CD34+ in patients with not surgical aortic aneurysms.

Interventions

BIOLOGICALblood taking

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Patients aged 18 or more. 2. Patients diagnosed with a thoracic or abdominal aortic aneurysm with no indication for surgical treatment (diameters \> 30 mm but \< 50 mm). 3. Patients accepting to sign a specific informed consent.

Exclusion criteria

1. Unstable coronary artery disease. 2. Congenital heart disease. 3. Any evolving infectious syndrome or viral infection (HIV, HBV or HCV). 4. Any chronic inflammatory or autoimmune disease. 5. Prior administration of G-CSF; EPO; GM-CSF. 6. Liver failure. 7. Prior oncologic disease or ongoing cancer with a life expectancy \< 1 year. 8. Dementia. 9. Pregnancy. 10. Patients aged \< 18.

Design outcomes

Primary

Measure	Time frame
progenitor cells CD34+ blood levels	At diagnosis of aneurysm

Countries

France

Contacts

Primary ContactAndrea PERROTTI, MD

aperrotti@chu-besancon.fr

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026